| DB ID | MyCo_4119 |
| Title | Analysis of Intestinal Mycobiota of Patients with Clostridioides difficile Infection among a Prospective Inpatient Cohort |
| Year | 2022 |
| PMID | 35867408 |
| Fungal Diseases involved | Clostridioides difficile infection |
| Associated Medical Condition | None |
| Genus | Clostridioides |
| Species | difficile |
| Organism | Clostridioides difficile |
| Ethical Statement | This study was approved by the institutional review board (IRB) of Beth Israel Deaconess Medical Center (IRB protocols 2016P000026 and 2016P000054). |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body extracts |
| Sample source | Stool |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | IL-4 |
| Biomarker Full Name | Interleukin-4 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Here, reported the gut mycobiota composition of 149 uniquely well characterized participants from a prospective clinical cohort and evaluate the discriminating ability of gut mycobiota to classify CDI and non-CDI patients. |
| Cohort No. | 149 |
| Age Group | >18 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Immunological assay |
| Analysis Method | Immunological assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Fungal correlation networks analysis, Immunological assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
